论文部分内容阅读
［目的］观察托马克（长春地辛VDS）对原发性肺癌的疗效。[方法]应用含托马克的联合化疗对59例晚期原发性支气管肺癌患者进行了Ⅲ期临床研究。其中非小细胞肺癌（NSCLC）50例，小细胞肺癌（SCLC）9例。（结果）肺癌化疗总有效率达54．2％，NSCLC及SCLC有效率分别为50．0％及77．8％。化疗毒副反应以骨髓抑制、胃肠道反应及脱发为主。［结论］托马克的临床疗效及毒副反应与国外长春地辛同类产品相似。可广泛应用于支气管肺癌的临床治疗中。
[Objective] To observe the effect of Tolimk (VDS) on primary lung cancer. [Methods] A phase III clinical study was performed on 59 patients with advanced primary bronchial lung cancer using combination chemotherapy with Tolmark. Of these, 50 were non-small cell lung cancer (NSCLC) and 9 were small cell lung cancer (SCLC). (Results) The total effective rate of lung cancer chemotherapy was 54.2%, and the effective rates of NSCLC and SCLC were 50.0% and 77.8%, respectively. The toxicities of chemotherapy were mainly bone marrow suppression, gastrointestinal reactions and alopecia. [Conclusion] Tomac’s clinical efficacy and toxic side effects are similar to those of similar products of Changchun Dixin abroad. Can be widely used in the clinical treatment of lung cancer.